Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and Connected Persons, in compliance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding share awards rather than a financial performance report.
Material Changes
On September 24, 2014, share awards were made under the GlaxoSmithKline 2009 Share Value Plan, resulting in the following changes in interests:
- Mrs V A Whyte: Received 10,050 Ordinary Shares.
- Mr P Thomson and Mrs K Thomson: Received 2,215 Ordinary Shares.
- Dr M Slaoui (Executive Director) and Dr K Slaoui: Received 2,300 Ordinary Shares.
No American Depositary Shares (ADS) were awarded in these specific transactions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions.
Important Facts for Investors
- Transaction Date: Awards were made on September 24, 2014, with notification filed on September 25, 2014.
- Market Prices: The closing middle market price on September 24, 2014, was £14.285 per Ordinary Share and $47.030 per ADS.
- Plan Details: All awards were issued under the GlaxoSmithKline 2009 Share Value Plan.
- Scope: This filing does not contain financial results or strategic updates for the company.